Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
This large VA observational study suggests that concomitant use of spironolactone does not compromise cancer control or survival of metastatic prostate cancer patients treated with abiraterone.
Authors
- Erum Z. Whyne (ORCID: https://orcid.org/0000-0003-4950-4405)
- Haekyung Jeon‐Slaughter (ORCID: https://orcid.org/0000-0002-5753-2935)
- Jonathan E. Dowell (ORCID: https://orcid.org/0000-0002-0202-9697)
- Katherine Kelly (ORCID: https://orcid.org/0009-0002-8405-3013)
Institutions
- VA North Texas Health Care System (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- The Prostate
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1002/pros.24811
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- U.S. Department of Veterans Affairs